logo
Athenex_Logo
“We are excited by the promise of our innovative, first-in-class NKT cell therapy platform with potential for improved efficacy, safety, and accessibility over current cell therapy approaches.

Athenex Provides Third Quarter 2022 Financial Results and Business Update

Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today provided a corporate and financial update for the third quarter ended September 30, 2022

By Athenex, Inc.
Published - Nov 03, 2022, 07:07 AM ET
Last Updated - Mar 19, 2024, 10:11 AM EDT
  • Bolstered balance sheet with $30 million public offering of common stock and warrants
  • Nasdaq Hearing Panel grants Athenex’s request for continued listing
  • Athenex is in the final stages of closing the sale of the China API operations
    • Article Source
    Quick Links
    Categories
    Our Offices
    • 10kInfo, Inc.
      13555 SE 36th St
      Bellevue, WA 98006
    • 10kInfo Data Solutions, Pvt Ltd.
      Claywork Create
      11 km, Arakere Bannerghatta Rd, Omkar Nagar, Arekere,
      Bengaluru, Karnataka 560076
    4.2 12182024